Obinutuzumab (Gazyva ) will be listed on the PBS from 1 October for as a first line treatment for advanced follicular lymphoma. The immunotherapy agent will be subsidised for previously untreated patients with stage II bulky or stage III/IV follicular lymphoma. It will also be listed for patients with rituximab-refractory follicular lymphoma. The decision, following ...
New PBS listings for lymphoma and MM treatments
By Michael Woodhead
18 Sep 2018